posted on 2023-03-31, 17:34authored byAnne T. Nies, Elke Schaeffeler, Heiko van der Kuip, Ingolf Cascorbi, Oliver Bruhn, Michael Kneba, Christiane Pott, Ute Hofmann, Christopher Volk, Shuiying Hu, Sharyn D. Baker, Alex Sparreboom, Peter Ruth, Hermann Koepsell, Matthias Schwab
<p>PDF file 79K, Supplementary Figure S1: Uptake of imatinib and OCT1 probe substrate TEA into OCT1-expressing cells and vector-transfected control cells Supplementary Figure S2: Cellular uptake of the OCT1 probe substrate TEA and imatinib into mOct1- or mOct2-expressing HEK293 cells Supplementary Figure S3: Cellular uptake of imatinib into the CML cell lines Meg-01, LAMA-84 and K562 as well as into OCT1-expressing HEK cells and vector-transfected control cells measured after an incubation period of 120 minutes Supplementary Figure S4: Cellular uptake of imatinib into HEK cells expressing variant V408 in comparison to HEK cells expressing reference sequence M408 and vector-transfected control cells measured after an incubation period of 10 minutes Supplementary Figure S5: Knockdown of OCT1 protein expression by the used shRNA</p>